-
1Academic Journal
Authors: Yu. V. Shevchuk, I. I. Shamigulov, I. V. Sychev, A. V. Kryukov, I. I. Temirbulatov, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, V. I. Vechorko, O. V. Averkov, D. A. Sychev, Ю. В. Шевчук, И. И. Шамигулов, И. В. Сычев, А. В. Крюков, И. И. Темирбулатов, К. Б. Мирзаев, Н. П. Денисенко, Ш. П. Абдуллаев, С. Н. Тучкова, В. И. Вечорко, О. В. Аверков, Д. А. Сычев
Contributors: Данная работа выполнена при финансовой поддержке Министерства здравоохранения Российской Федерации, тематика государственного задания «Разработка системы поддержки принятия врачебных решений для прогнозирования нежелательных лекарственных реакций у пациентов с COVID-19 на основе фармакогенетического тестирования» (ЕГИСУ НИОКТР № 122021800321-2).
Source: Acta Biomedica Scientifica; Том 9, № 6 (2024); 52-62 ; 2587-9596 ; 2541-9420
Subject Terms: модель риска, remdesivir, adverse drug reactions, hepatotoxicity, pharmacogenetic testing, predictors of adverse reactions, machine learning, risk model, ремдесивир, нежелательные реакции, гепатотоксичность, фармакогенетическое исследование, предикторы нежелательных реакций, машинное обучение
File Description: application/pdf
Relation: https://www.actabiomedica.ru/jour/article/view/5118/2933; Временные методические рекомендации по профилактике, диагностике и лечению новой коронавирусной инфекции (COVID-19). М.; 2023.; Gilead Sciences Biopharmaceutical Companies, Veklury (remdesivir). U.S. Food and Drug Administration. 2022. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214787Orig1s010Lbl.pdf. [date of access: 20.05.2024].; Pantazis N, Pechlivanidou E, Antoniadou A, Akinosoglou K, Kalomenidis I, Poulakou G, et al. Remdesivir: Effectiveness and safety in hospitalized patients with COVID-19 (ReEs-COVID-19) – Analysis of data from daily practice. Microorganisms. 2023; 11(8): 1998. doi:10.3390/microorganisms11081998; Kang H, Kang CK, Im JH, Cho Y, Kang DY, Lee JY. Adverse drug events associated with remdesivir in real-world hospitalized patients with COVID-19, including vulnerable populations: A retrospective multicenter study. J Korean Med Sci. 2023; 38(44): e346. doi:10.3346/jkms.2023.38.e346; Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236): 1569-1578. doi:10.1016/S0140-6736(20)31022-9; Шевчук Ю.В., Крюков А.В., Темирбулатов И.И., Сычев И.В., Мирзаев К.Б., Денисенко Н.П., и др. Модель прогнозирования риска развития лекарственного поражения печени на фоне терапии ремдесивиром: обсервационное проспективное открытое контролируемое исследование. Фармация и фармакология. 2023; 11(3): 228-239. doi:10.19163/2307-9266-2023-11-3-228-239; Falconer N, Barras M, Cottrell N. Systematic review of predictive risk models for adverse drug events in hospitalized patients. Br J Clin Pharmacol. 2018; 84: 846-864. doi:10.1111/bcp.13514; Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S, et al. The use of artificial intelligence in pharmacovigilance: A systematic review of the literature. Pharm Med. 2022; 36(5): 295-306. doi:10.1007/s40290-022-00441-z; Goldberger J, Roweis ST, Hinton GE, Salakhutdinov R. Neighbourhood components analysis. 2004: 513-520.; Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. 2013.; Cervantes J, Garcia-Lamont F, Rodríguez-Mazahua L, Lopez A. A comprehensive survey on support vector machine classification: Applications, challenges and trends. Neurocomputing. 2020; 408: 189-215. doi:10.1016/j.neucom.2019.10.118; Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. 2017. 13. Biau G, Scornet E. A random forest guided tour. TEST. 2016; 25(1): 197-227. doi:10.1007/s11749-016-0481-7; Prokhorenkova L, Gusev G, Vorobev A, Dorogush AV, Gulin A. CatBoost: Unbiased boosting with categorical features. Advances in Neural Information Processing Systems. 2018; 31.; Hossin M, Sulaiman MN. A review on evaluation metrics for data classification evaluations. Int J Data Min Knowl Manag Process. 2015; 5(2): 1. doi:10.5121/ijdkp.2015.5201; O’Mahony D, O’Connor MN, Eustace J, Byrne S, Petrovic M, Gallagher P. The adverse drug reaction risk in older persons (ADRROP) prediction scale: Derivation and prospective validation of an ADR risk assessment tool in older multi-morbid patients. Eur Geriatr Med. 2018; 9(2): 191-199. doi:10.1007/s41999-018-0030-x; Lavan A, Eustace J, Dahly D, Flanagan E, Gallagher P, Cullinane S, et al. Incident adverse drug reactions in geriatric inpatients: A multicentred observational study. Ther Adv Drug Saf. 2018; 9(1): 13-23. doi:10.1177/2042098617736191; Yadesa TM, Kitutu FE, Tamukong R, Alele PE. Development and validation of ‘Prediction of Adverse Drug Reactions in Older Inpatients (PADROI)’ risk assessment tool. Clin Interv Aging. 2022; 17: 195-210. doi:10.2147/CIA.S350500; Zhang F, Sun B, Diao X, Zhao W, Shu T. Prediction of adverse drug reactions based on knowledge graph embedding. BMC Med Inform Decis Mak. 2021; 21: 1-11. doi:10.1186/s12911-021-01402-3; Galeano D, Li S, Gerstein M, Paccanaro A. Predicting the frequencies of drug side effects. Nat Commun. 2020; 11(1): 4575. doi:10.1038/s41467-020-18305-y; Choudhury O, Park Y, Salonidis T, Gkoulalas-Divanis A, Sylla I, Das AK. Predicting adverse drug reactions on distributed health data using federated learning. AMIA Annu Symp Proc. 2019; 2019: 313-322.; Ayyashi M, Darbashi H, Hakami A, Sharahili F. Evaluation of remdesivir utilization pattern in critically ill patients with COVID-19 in Jazan Province. Cureus. 2023; 15(3): e36247. doi:10.7759/cureus.36247; Iloanusi S, Mgbere O, Essien EJ. Polypharmacy among COVID-19 patients: A systematic review. J Am Pharm Assoc. 2021; 61(5): e14-e25. doi:10.1016/j.japh.2021.05.006; Lee JY, Ang ASY, Mohd Ali N, Ang LM, Omar A. Incidence of adverse reaction of drugs used in COVID-19 management: A retrospective, observational study. J Pharm Policy Pract. 2021; 14: 1-9. doi:10.1186/s40545-021-00370-3; Sendekie AK, Kasahun AE, Limenh LW, Dagnaw AD, Belachew EA. Clinical and economic impact of adverse drug reactions in hospitalised patients: Prospective matched nested case-control study in Ethiopia. BMJ Open. 2023; 13: e073777. doi:10.1136/ bmjopen-2023-073777; Blair HA. Remdesivir: A review in COVID-19. Drugs. 2023; 83(13): 1215-1237. doi:10.1007/s40265-023-01926-0; Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, et al. CYP3A4 and CYP3A5 genotyping recommendations: A joint consensus recommendation of the association for molecular pathology, clinical pharmacogenetics implementation consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn. 2023; 25(9), 619-629. doi:10.1016/j.jmoldx.2023.06.008; Buscemi S, Corleo D, Randazzo C. Risk factors for COVID-19: Diabetes, hypertension, and obesity. Coronavirus Therapeutics, Volume II: Clinical Management and Public Health. 2022; 115-129. doi:10.1007/978-3-030-85113-2_7; Zhang X, Ha S, Lau HCH, Yu J. Excess body weight: Novel insights into its roles in obesity comorbidities. Semin Cancer Biol. 2023; 92: 16-27. doi:10.1016/j.semcancer.2023.03.008; Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023; 8(1): 20-30. doi:10.1016/S2468-1253(22)00317-X; https://www.actabiomedica.ru/jour/article/view/5118
-
2Academic Journal
Authors: I. V. Sychev, N. P. Denisenko, A. A. Kachanova, A. V. Lapshtaeva, Sh. P. Abdullaev, L. N. Goncharova, K. B. Mirzaev, D. A. Sychev, И. В. Сычев, Н. П. Денисенко, А. А. Качанова, А. В. Лапштаева, Ш. П. Абдуллаев, Л. Н. Гончарова, К. Б. Мирзаев, Д. А. Сычев
Contributors: This study was sponsored by the Ministry of Health of the Russian Federation. It was carried out as part of publicly funded research project “New Pharmacogenetic Biomarkers of the Safety of Pharmacotherapy of Certain Socially Significant Diseases” (Unified State Information System for Accounting of Scientific Research, Experimental Design and Technological Works for Civil Purposes, No. 121110800062-6)., Работа выполнена при финансовой поддержке Министерства здравоохранения Российской Федерации. Тематика государственного задания: «Новые фармакогенетические биомаркеры безопасности фармакотерапии некоторых социально-значимых заболеваний» (ЕГИСУ НИОКТР № 121110800062-6).
Source: Safety and Risk of Pharmacotherapy; Том 11, № 2 (2023); 231-240 ; Безопасность и риск фармакотерапии; Том 11, № 2 (2023); 231-240 ; 2619-1164 ; 2312-7821
Subject Terms: клиническое исследование, enalapril, dry cough, adverse drug reaction, adverse drug reaction predictors, cardiovascular pathology, history of allergies, clinical study, эналаприл, сухой кашель, нежелательная реакция, предикторы нежелательных реакций, кардиоваскулярная патология, аллергологический анамнез
File Description: application/pdf
Relation: https://www.risksafety.ru/jour/article/view/361/789; https://www.risksafety.ru/jour/article/downloadSuppFile/361/323; https://www.risksafety.ru/jour/article/downloadSuppFile/361/325; https://www.risksafety.ru/jour/article/downloadSuppFile/361/326; https://www.risksafety.ru/jour/article/downloadSuppFile/361/327; https://www.risksafety.ru/jour/article/downloadSuppFile/361/363; Chan NJ, Soliman AM. Angiotensin converting enzyme inhibitor-related angioedema: onset, presentation, and management. Ann Otol Rhinol Laryngol. 2015;124(2):89–96. https://doi.org/10.1177/0003489414543069; Soo Hoo GW, Lin HK, Junaid I, Klaustermeyer WB. Angiotensin-converting enzyme inhibitor angioedema requiring admission to an intensive care unit. Am J Med. 2015;128(7):785–9. https://doi.org/10.1016/j.amjmed.2015.02.006; Brugts JJ. Discontinuation of angiotensin conver ting enzyme inhibitors due to dry cough: incidence and clinical determinants. Clin Pharmacol Ther. 2019;105(3):563. https://doi.org/10.1002/cpt.1130; Borghi C, Cicero AF, Agnoletti D, Fiorini G. Pathophysiology of cough with angiotensin-converting enzyme inhibitors: how to explain within-class differences? Eur J Intern Med. 2023;110:10–5. https://doi.org/10.1016/j.ejim.2023.01.005; Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499–509. https://doi.org/10.1111/j.1365-2753.2003.00484.x; Ng LP, Goh PS. Incidence of discontinuation of angiotensin-converting enzyme inhibitors due to cough, in a primary healthcare centre in Singapore. Singapore Med J. 2014;55(3):146–9. https://doi.org/10.11622/smedj.2014034; Nasser J, Al Aradi K, Kubra SE, Omran A. High incidence of cough among users of angiotensin-converting enzyme inhibitors. Bahrain Med Bull. 2018;40(2):97–9. https://doi.org/10.12816/0047558; Jamshed F, Jaffry H, Hanif H, Kumar V, Naz U, Ahmed M, Fareed S. Demographic and clinical characteristics of patients presenting with angiotensin-converting enzyme inhibitors induced cough. Cureus. 2019;11(9):e5624. https://doi.org/10.7759/cureus.5624; Lavorini F, Chellini E, Innocenti M, Campi G, Egan CG, Mogavero S, Fontana GA. A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. Cough. 2014;10(1):7. https://doi.org/10.1186/s12997-014-0007-5; Boonyapisit W, Tresukosol D. Comparison of the incidence of imidapril and enalapril induced cough. J Med Assoc Thai. 2010;93 Suppl 1:S48–53. PMID: 20364557; Loo HC, Osman F, Ho SL, An SY, Yong YMA, Khoo EM. Incidence of angiotensin-converting enzyme inhibitor-induced cough in a Malaysian public primary care clinic: a retrospective cohort study. Malays Fam Physician. 2022;17(1):66–70. https://doi.org/10.51866/oa.80; Liang L, Kung JY, Mitchelmore B, Gill J, Cave A, Banh HL. Angiotensin-converting enzyme inhibitor induced cough in Chinese patients: a systematic review and meta-analysis. J Pharm Pharm Sci. 2021;24:137–47. https://doi.org/10.18433/jpps31632; Mateti UV, Nekkanti H, Vilakkathala R, Rajakannan T, Mallayasamy S, Ramachandran P. Pattern of angiotensin-converting enzyme inhibitors induced adverse drug reactions in South Indian teaching hospital. N Am J Med Sci. 2012;4(4):185–9. https://doi.org/10.4103/1947-2714.94945; Olowofela AO, Isah AO. A profile of adverse effects of antihypertensive medicines in a tertiary care clinic in Nigeria. Ann Afr Med. 2017;16(3):114-119. https://doi.org/10.4103/aam.aam_6_17; Schröder H. Reizhusten bei ACE-Hemmer-Einnahme [Dry cough from ACE inhibitors]. Med Monatsschr Pharm. 2005;28(9):321–2. German. PMID: 16163883; Tebha SS, Zaidi ZA, Sethar S, Virk MAA, Yousaf MN. Angiotensin converting enzyme inhibitor associated spontaneous herniation of liver mimicking a pleural mass: a case report. World J Hepatol. 2022;14(4):854–9. https://doi.org/10.4254/wjh.v14.i4.854; Trovato DA, Sousa JE, Bruetman JE, Finn BC, Young P. Fracturas costales simétricas asociadas a tos [Symmetrical rib fractures associated with chronic cough. Report of one case]. Rev Med Chil. 2018;146(3):391–3. Spanish. https://doi.org/10.4067/s0034-98872018000300391; Pinto B, Jadhav U, Singhai P, Sadhanandham S, Shah N. ACEI-induced cough: a review of current evidence and its practical implications for optimal CV risk reduction. Indian Heart J. 2020;72(5):345–50. https://doi.org/10.1016/j.ihj.2020.08.007; Fox AJ, Lalloo UG, Belvisi MG, Bernareggi M, Chung KF, Barnes PJ. Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med. 1996;2(7):814–7. https://doi.org/10.1038/nm0796-814; Yılmaz İ. Angiotensin-converting enzyme inhibitors induce cough. Turk Thorac J. 2019;20(1):36–42. https://doi.org/10.5152/TurkThoracJ.2018.18014; Fernandez-Rando M, Herrera MD, Almeida-González CV, Grilo A. Days needed for the disappearance of a cough due to the use of an angiotensin-converting enzyme inhibitor and identification of predisposing factors associated with its appearance in a clinical cohort of hypertensive patients. J Clin Pharmacol. 2021;61(5):591–7. https://doi.org/10.1002/jcph.1786; Teklay G, Gebremedhin A, Ayalew E. Prevalence of cough among patients treated with angiotensin converting enzyme inhibitors. International Journal of Pharma Sciences and Research. 2014;12(5):992–8.; Sato A, Fukuda S. A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. Clin Exp Hypertens. 2015;37(7):563–8. https://doi.org/10.3109/10641963.2015.1026040; Wyskida K, Jura-Szołtys E, Smertka M, Owczarek A, Chudek J. Factors that favor the occurrence of cough in patients treated with ramipril—a pharmacoepidemiological study. Med Sci Monit. 2012;18(9):PI21–8. https://doi.org/10.12659/msm.883336; https://www.risksafety.ru/jour/article/view/361